8-K: Tonix Pharmaceuticals Announces Positive Bridging Study Results for Tonmya in Japan and China

Tonix Pharmaceuticals reports successful pharmacokinetic bridging study results for Tonmya, supporting regulatory filings in Japan and China.

Summary

• Tonix Pharmaceuticals announced positive results from a clinical pharmacokinetic (PK) bridging study of Tonmya in healthy Japanese and Chinese volunteers.
• The study compared the PK profile of Tonmya in these volunteers to a previous study in Caucasian volunteers.
• Results showed that key PK parameters of cyclobenzaprine were similar across all three groups, with geometric mean ratios within the 90% confidence interval.
• Tonmya was found to be safe and well-tolerated at doses up to 5.6 mg.
• The company expects these results to support regulatory filings for clinical studies in Japan and China, where cyclobenzaprine is a new chemical entity.
• Tonix plans to meet with regulatory agencies in Japan and China to advance the development of Tonmya.
• The study was a randomized, single-dose, open-label, 2-way, crossover study design with 10 Japanese and 10 Chinese volunteers.
• The primary objective was to assess the PK profile and dose proportionality of Tonmya at 2.8 mg and 5.6 mg doses.
• The company holds patents for market exclusivity of Tonmya in Japan, China, Hong Kong, and Taiwan, expected to last until 2034.

Sentiment

Score: 8

Explanation: The document presents positive results from a key clinical study, supporting regulatory filings in major markets and indicating a strong potential for future growth. The company also has strong patent protection in place.

Positives

• The pharmacokinetic bridging study of Tonmya in Japanese and Chinese volunteers showed positive results.
• The PK parameters were similar to those in Caucasian volunteers, indicating no need for dosage adjustments.
• Tonmya was well-tolerated with a low incidence of adverse events.
• The study results are expected to support regulatory filings in Japan and China.
• Tonix has strong patent protection for Tonmya in key Asian markets until 2034.
• The company plans to submit an NDA to the FDA in the second half of 2024 for Tonmya for the management of fibromyalgia.

Risks

• The company's future success depends on obtaining regulatory approvals in Japan and China.
• There are risks associated with the clinical development and commercialization of new products.
• The company faces competition in the pharmaceutical market.
• The company's ability to secure partnerships in Asia is not guaranteed.
• The company's success is dependent on the FDA approval of Tonmya in the US.

Future Outlook

Tonix plans to submit a New Drug Application (NDA) to the U.S. FDA for Tonmya in the second half of 2024 and is seeking regulatory approval in Japan and China. The company intends to meet with regulatory agencies in Japan and China to further the development of Tonmya.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that the results show a similar pharmacokinetic profile in ethnic Japanese and Chinese volunteers with a Caucasian comparator group.
• Dr. Lederman believes that these data, along with the positive Phase 3 RESILIENT study results, are sufficient to support regulatory filings in Japan and China.
• Dr. Lederman also noted that Tonmya would be a welcome addition to the therapeutic options for fibromyalgia patients in East Asia and an attractive asset for the right development and commercialization partners in these markets.

Industry Context

This announcement is significant as it demonstrates Tonix's progress in expanding the potential market for Tonmya beyond the U.S. The successful bridging study is a crucial step for regulatory approval in Japan and China, which are large pharmaceutical markets. The company is also seeking partners in these markets.

Comparison to Industry Standards

• The bridging study design is consistent with industry standards for demonstrating the applicability of clinical data across different ethnic populations.
• The use of a Caucasian comparator group is a common practice in pharmacokinetic studies.
• The 90% confidence interval for geometric mean ratios is a standard criterion for demonstrating similarity in PK parameters.
• The safety and tolerability results are in line with expectations for a sublingual formulation of cyclobenzaprine.
• Other companies such as Teva and Mylan have also conducted similar bridging studies for their products in different markets.

Stakeholder Impact

• Shareholders may view the positive study results as a positive development for the company's future prospects.
• The results could lead to increased interest from potential partners in Japan and China.
• Patients in Japan and China may benefit from the availability of Tonmya as a treatment option for fibromyalgia.
• Employees may be positively impacted by the company's progress and potential for growth.

Next Steps

• Tonix plans to file a Clinical Trial Notification (CTN) in Japan and an Investigational New Drug (IND) application in China.
• The company intends to meet with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and the National Medical Products Administration (NMPA) in China.
• Tonix plans to submit a New Drug Application (NDA) to the U.S. FDA for Tonmya in the second half of 2024.

Key Dates

Keywords

Tonmya, TNX-102 SL, cyclobenzaprine, pharmacokinetic, bridging study, Japan, China, regulatory filings, fibromyalgia, clinical trials